Zofran birth defect litigation in the United States has effectively concluded, with no active lawsuits or new claims being accepted as of April 2026. The main U.S. multidistrict litigation involving 430 cases was dismissed in June 2021 by federal court based on preemption grounds, a decision upheld by the Court of Appeals in January 2023. This means pregnant women who took Zofran (ondansetron) and had children with birth defects can no longer pursue compensation through the American legal system, though some Canadian proceedings were only recently discontinued.
The litigation arose because GlaxoSmithKline promoted Zofran off-label for pregnancy-related nausea despite the drug never being FDA-approved for use during pregnancy. A mother in the early 2000s who took Zofran for severe morning sickness and later gave birth to a child with a cleft palate or congenital heart defect represents the typical case profile. The U.S. Department of Justice itself settled with GlaxoSmithKline in 2013 for $3 billion due to the company’s unlawful off-label promotion practices.
Table of Contents
- What Is Zofran and Why Was It Used During Pregnancy?
- The Research Linking Zofran to Birth Defects
- The FDA’s Warning and Regulatory Response
- The Criminal Settlement with GlaxoSmithKline
- The Dismissal of U.S. Litigation and Final Court Rulings
- Canadian Class Action Discontinuance
- Current Status and Why No New Cases Are Being Accepted
- Conclusion
What Is Zofran and Why Was It Used During Pregnancy?
Zofran (ondansetron) is an anti-nausea medication initially approved by the FDA in 1991 specifically for cancer patients undergoing chemotherapy and radiation therapy. The drug works by blocking serotonin receptors in the brain and gastrointestinal tract that trigger nausea and vomiting. Despite lacking any FDA approval for pregnancy use, physicians began prescribing Zofran off-label to pregnant women suffering from severe morning sickness (hyperemesis gravidarum) because the drug was perceived as safer than older anti-nausea alternatives and had strong anti-vomiting effectiveness.
GlaxoSmithKline actively promoted Zofran’s off-label use during pregnancy through marketing campaigns targeting obstetricians, claiming it was a preferred option for pregnancy-related nausea. This marketing drove significant off-label prescriptions, even though the company had never conducted the clinical trials necessary to establish safety for fetal development. Pregnant women taking Zofran during the 1990s and 2000s often had no idea the medication was unapproved for their condition, trusting their doctors’ prescriptions based on pharmaceutical company promotion rather than rigorous safety evidence.
The Research Linking Zofran to Birth Defects
A landmark 2012 study by researchers at Harvard and boston University analyzing pregnancy registries found that babies exposed to Zofran during the first trimester had a 237 percent increased risk of developing cleft palate compared to unexposed pregnancies. This was a dramatic finding that suggested even brief exposure to ondansetron during early pregnancy—when oral structures and heart tissues are forming—posed significant risk. The study analyzed thousands of pregnancies and represented one of the largest associations ever found between a single medication exposure and this specific birth defect. Additional research identified increased risk of congenital cardiac malformations, with one large study of 900,000 pregnancies finding a 2-fold elevated risk of heart defects and a 30 percent overall increased risk of major congenital malformations among children exposed to Zofran in utero.
However, the scientific picture grew more complicated over time. A 2019 updated review synthesizing nine different studies concluded that ondansetron use during pregnancy was “not associated with a significant increase in rate of major or selected subgroups of malformations,” suggesting that earlier findings might have been due to other confounding factors or methodological limitations. This contradiction between studies represents a critical limitation in the Zofran litigation: no definitive consensus emerged about whether the drug actually caused birth defects or whether other factors during pregnancy explained the observed associations. This scientific uncertainty played a significant role in why courts eventually dismissed lawsuits, finding that plaintiffs could not meet the legal burden of proving causation beyond a reasonable scientific basis.
The FDA’s Warning and Regulatory Response
The FDA issued a black box warning for Zofran in 2012 specifically noting the risk of QT interval prolongation—a dangerous disruption of the heart’s electrical rhythm that can cause fatal arrhythmias. This warning applied to the general population but carried particular concern for pregnant women, whose cardiovascular systems already undergo significant changes during pregnancy. The agency subsequently warned against Zofran use in pregnancy based on studies showing associations with congenital cardiac malformations and oral clefts, effectively confirming that the drug posed recognized risks to fetal development.
Despite these FDA warnings, the damage from off-label prescribing had already occurred. Thousands of women had taken Zofran during pregnancy throughout the 1990s and 2000s before the warnings were issued, and many physicians continued off-label prescribing after the warnings as well, interpreting the FDA’s statements as insufficient to prohibit medical judgment. The regulatory response came too late to prevent the exposure of a generation of fetuses and too weak to halt off-label prescribing through medical practice alone.
The Criminal Settlement with GlaxoSmithKline
In 2013, the U.S. Department of Justice settled with GlaxoSmithKline for $3 billion—one of the largest pharmaceutical settlements in history—specifically because the company had knowingly and systematically promoted Zofran off-label for pregnancy-related nausea and other non-approved medical conditions. The settlement acknowledged that GlaxoSmithKline engaged in illegal marketing practices, paying kickbacks to healthcare providers and distributing misleading promotional materials. This criminal settlement established that the company understood Zofran lacked approval for pregnancy use yet chose to market it anyway.
Despite this DOJ settlement establishing corporate wrongdoing, the settlement did not automatically provide compensation to affected patients or families. The $3 billion was a penalty to the government, not a compensation fund for patients harmed by the off-label promotion. This represents a significant gap in the justice system: the government can penalize corporations for illegal promotion, but injured individuals must prove their cases separately in civil litigation. Families affected by Zofran-related birth defects were required to pursue their own lawsuits against GlaxoSmithKline rather than receiving automatic compensation from the criminal settlement.
The Dismissal of U.S. Litigation and Final Court Rulings
The central U.S. multidistrict litigation involving 430 Zofran birth defect cases was dismissed in June 2021 by Judge Dennis Saylor IV in the U.S. District Court for the District of Massachusetts. Judge Saylor ruled that the cases were preempted by federal law—meaning that FDA approval (or lack thereof) of a drug prevents states from imposing liability for injuries allegedly caused by that drug when the drug was used off-label. This federal preemption doctrine holds that the FDA’s regulatory decisions about drug approval supersede state-level personal injury lawsuits. The ruling effectively ended all pending litigation at the federal level. Plaintiffs appealed the dismissal to the U.S.
Court of Appeals for the First Circuit, which affirmed Judge Saylor’s decision in January 2023. This meant that the preemption ruling was upheld and no further appellate review was available. As a final blow, in March 2024, the court ordered the plaintiffs in the litigation to pay GlaxoSmithKline $453,989 in litigation costs—meaning that families who had pursued these lawsuits not only lost their cases but were forced to pay the defendant’s legal fees. This cost-shifting ruling discouraged any remaining attempts at legal action and demonstrated the significant financial risks of pursuing failed litigation. A critical warning for potential claimants: the dismissal of U.S. litigation means that no class action settlement fund exists. Families cannot file a claim with an administrator to receive compensation. Instead, they would need to independently negotiate with GlaxoSmithKline or pursue state-level claims, both of which face substantial legal barriers and have produced no successful outcomes.
Canadian Class Action Discontinuance
Parallel to the U.S. litigation, Canadian class actions were pursued in Ontario and Quebec on behalf of Canadian residents. These actions survived longer than the U.S. cases but ultimately met the same fate. The Ontario class action was discontinued with court approval effective February 26, 2025, and the Quebec class action was discontinued effective July 31, 2025.
The discontinuance of both Canadian proceedings means that North American litigation on Zofran birth defects has completely ended. Affected families in Canada lost their final opportunity to pursue legal remedies, and no settlement was reached with any defendant. The closure of Canadian proceedings represents the final chapter in organized litigation against Zofran manufacturers. Unlike some mass tort situations where Canadian and U.S. litigation proceed in parallel and sometimes reach different outcomes, the Zofran cases converged toward the same outcome: no compensation for affected families, no class action settlement, and no legal remedy available.
Current Status and Why No New Cases Are Being Accepted
As of April 2026, no attorney is actively accepting new Zofran birth defect cases, and the litigation landscape has completely closed. The combination of the U.S. federal court dismissals, appellate affirmation, and Canadian discontinuance has effectively eliminated any viable legal pathway for compensation.
Law firms that previously marketed Zofran claims have removed these cases from their websites or now direct inquiries to public health resources rather than legal representation. This closed-door status reflects the reality that courts determined preemption bars such claims and that the scientific evidence remained too contested to support causation beyond a reasonable degree of scientific certainty. Without a successful lawsuit to establish liability, settlements become impossible, and without settlements, law firms cannot recover contingency fees. The financial incentive to pursue these cases has evaporated, leaving families without legal representation and without remedy.
Conclusion
Zofran birth defect litigation represents a closed chapter in American pharmaceutical law. The U.S. multidistrict litigation of 430 cases was dismissed based on federal preemption, affirmed on appeal, and Canadian parallel actions were discontinued by 2025. No settlement fund exists, no new cases are being accepted, and no compensation mechanism is available for families whose children were born with cleft palate, cardiac defects, or other malformations after prenatal Zofran exposure.
The only successful legal action against GlaxoSmithKline—the 2013 DOJ settlement for $3 billion—resulted in corporate penalties but not patient compensation. Families affected by potential Zofran-related birth defects should understand that the legal avenue for compensation has permanently closed. While the scientific debate about causation continues—with some studies showing elevated risk and others finding no association—courts determined that this scientific uncertainty precluded liability under federal law. The best course of action for affected families is to consult with genetic counselors, pediatric specialists, and state-level support programs for children with birth defects, rather than seeking legal representation for litigation that is no longer viable.